Affiliation:
1. Department of Pharmacy Research
2. Office for Research, Hartford Hospital, Hartford, Connecticut 06102
3. Division of Infectious Diseases
Abstract
ABSTRACT
Cethromycin (ABT-773), a new ketolide, possesses potent in vitro activity against
Streptococcus pneumoniae
. The objective of this study was to investigate the in vivo bactericidal activity of cethromycin against macrolide-susceptible and -resistant
S. pneumoniae
in a murine pneumonia model and to describe the pharmacodynamic (PD) profile of cethromycin. Eight (two macrolide susceptible, six macrolide resistant) clinical isolates of
S. pneumoniae
were investigated. Cyclophosphamide administration rendered ICR mice transiently neutropenic prior to intratracheal inoculation with 0.05 ml of an
S. pneumoniae
suspension containing 10
7
to 10
8
CFU/ml. Oral cethromycin was initiated 12 to 14 h postinoculation over a dosage range of 0.1 to 800 mg/kg of body weight/day. Lungs from seven to eight mice per treatment and control groups were collected at 0 and 24 h posttherapy to assess bacterial density. The cumulative mortality (
n
= 12 to 13) was assessed at 120 h (end of therapy) and at 192 h (3 days posttherapy). Recovery of pneumococci from the lungs of infected animals prior to the initiation of therapy ranged from 4.6 to 7.2 log
10
CFU. Growth in untreated control animals over a 24-h study period increased 0.3 to 2.7 log
10
CFU. Cethromycin demonstrated a substantial bactericidal effect, regardless of macrolide susceptibility. Correlation between changes in bacterial density (24 h) and survival over both 120 and 192 h were statistically significant. All three PD parameters demonstrated a significant correlation with changes in log
10
CFU/lung (Spearman's correlation coefficient,
P
< 0.001); however, the goodness of fit as assessed with the maximum effect (
E
max
) model revealed that the maximum concentration of free drug in serum (
C
max free
)/MIC and the area under the free drug concentration-time curve (AUC
free
)/MIC best explained the relationship between drug exposure and reductions in viable bacterial counts. These data reveal that an approximate cethromycin AUC
free
/MIC of 50 or
C
max free
/MIC of 1 results in bacteriostatic effects, while higher values (twofold) maximize survival.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献